Paediatric snakebite envenoming: recognition and management of cases

Jacqueline Le Geyt, Sophie Pach, José María Gutiérrez, Abdulrazaq Garba Habib, Kalana Prasad Maduwage, Timothy Craig Hardcastle, Roger Hernández Díaz, María Luisa Avila-Aguero, Kyaw Thu Ya, David Williams, Jay Halbert

ABSTRACT
Snakebite in children can often be severe or potentially fatal, owing to the lower volume of distribution relative to the amount of venom injected, and there is potential for long-term sequelae. Due to their smaller size, children often present with more severe effects of snakebite, owing to their lower volume of distribution relative to the mass of injected venom. This higher ratio of venom to body mass can result in more rapid and severe neurotoxicity, coagulopathy and severe local tissue damage. This review describes the clinical presentation of snakebite envenoming in children, and its management, especially the challenges faced by clinicians in the low-income settings where snakebite is most common.

Snake venoms and antivenoms
Venoms are injected by the snake either subcutaneously or intramuscularly, or rarely intravenously. Many venoms inflict local tissue damage at the anatomical site of injection. Rare cases result in areas of necrosis that occur away from the bite site, such as by some species of spitting cobras. Venom toxins are absorbed by lymphatic and blood vessels to reach the circulation, causing systemic effects. An estimated quarter of bites from venomous snakes are ‘dry’ bites (this proportion varies with snake species), meaning that venom is not injected and envenoming does not occur; it is important to differentiate the autonomic manifestations of fear from actual systemic envenoming.

Snake venoms are complex mixtures of proteins. Viperid snake venoms are particularly rich in metalloproteinases, serine proteinases and phospholipases A2. Elapid venoms contain high amounts of proteins of the three-finger protein family and phospholipases A2. Many other protein families are also present in venoms and contribute to their toxicity, such as C-type lectin-like proteins, disintegrins and dendrotoxins.

What is already known?

► Snakebite in children disproportionately affects low-income settings.
► Most healthcare settings manage cases of snakebite envenoming using a syndromic approach.
► Antivenom is the mainstay of effective treatment.

What this study adds?

► When and how to give antivenom in the paediatric population.
► An approach to management of snakebite in children, including what to do and what not to do.

Local effects
Local effects at the bite site occur in bites inflicted by the majority of species of the family Viperidae and by some species of the family Elapidae, such as the spitting cobras. These local effects are usually pain, swelling, ecchymosis and blisters, sometimes causing significant local tissue necrosis, including myonecrosis and cutaneous necrosis (see figure 1). Swelling is often more severe and widespread in children, although does tend to recover faster than in adults, with most completely recovered in 1 month. There is, therefore, a risk of developing compartment syndrome, depending on the site of the bite, the volume and type of venom injected, and the local reaction.

INTRODUCTION
The global burden of snakebite is large, disproportionately affecting children who live in low-income settings, and often leads to permanent physical and psychological sequelae. Due to their smaller size, children often present with more severe effects of snakebite, owing to their lower volume of distribution relative to the mass of injected venom. This higher ratio of venom to body mass can result in more rapid and severe neurotoxicity, coagulopathy and severe local tissue damage. This review describes the clinical presentation of snakebite envenoming in children, and its management, especially the challenges faced by clinicians in the low-income settings where snakebite is most common.
Systemic capillary leakage syndrome, which contributes to hypo-volaemia and shock. A number of elapid and viper species can typically first appear as bilateral ptosis with or without ophthalmoplegia or diplopia. Some viperid species, such as the South American rattlesnake, also induce neuromuscular paralysis. A number of Australian elapid venoms also cause coagulopathy. Systemic manifestations of many viperid envenomings are typically associated with coagulopathy and bleeding, owing to the disruption of microvessels wall integrity by venom proteinases and to a consumption coagulopathy. Some viper bites do not cause coagulopathy. In severe cases, hypovolaemia secondary to coagulopathy, capillary leakage and vasoactive and myocardial depressant toxins can precipitate cardiovascular shock. Some venoms, such as that of Russell’s viper, cause a systemic capillary leakage syndrome, which contributes to hypovolaemia and shock. A number of elapid and viper species can cause acute kidney injury, owing to hypovolaemia, direct nephrotoxic effects, thrombotic microangiopathy or accumulation of myoglobin in renal tubules as a consequence of rhabdomyolysis. Recently, there have been increasing reports of sudden cardiorespiratory arrest associated with snakebite envenoming, due to cardiovascular toxicity of venoms.

A number of ‘colubrid’ species can cause life-threatening envenomation characterised by haemorrhage and coagulopathy, and some species (notably African boomslang Dispholidus typus and Japanese yamakagashi Rhabdophis tigrinus) have caused fatalities.

In Africa and some parts of the Middle East burrowing asps in the genus Atractaspis are common causes of nocturnal snakebites. Clinical signs include local pain, moderate to severe local and regional swelling, oedema, lymphadenopathy, blister and bleb formation and subsequent necrosis. Some species can cause cardiovascular effects, including direct cardiotoxicity induced by endothelin-like toxins (sarafotoxins). Table 1 summarises the most important systemic effects of snakebite envenoming.

### Management of paediatric snake envenoming

#### Community prehospital first aid

The child should be kept calm and comfortable, as a hyperdynamic state can accelerate dissemination of venom. Immobilisation of the bitten part of the body, in a functional position below the level of the heart, reduces lymphatic absorption of the venom. The immobilised child should be transferred to a medical facility as quickly as possible, with the focus on airway and breathing support, prevention of aspiration (of vomitus or other fluids), oxygen administration and gaining intravenous access in an unaffected limb, if available.

### Table 1  Mechanism, signs and symptoms of predominant snakebite envenoming systemic effects

<table>
<thead>
<tr>
<th>Mechanism</th>
<th>Typical symptoms and signs</th>
<th>Typical snakes associated</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurotoxic effects</td>
<td>Blockade at presynaptic and/or postsynaptic sites of neuromuscular junction: Descending paralysis, ptosis, ophthalmoplegia, salivation, dysphagia can progress to generalised flaccid paralysis and respiratory arrest</td>
<td>Elapids (mambas, cobras, kraits, some rattlesnakes)</td>
</tr>
<tr>
<td>Haemotoxic effects</td>
<td>Degradation of capillary basement membrane: Local and systemic bleeding</td>
<td>Viperids (saw-scaled vipers, puff adders, Russell’s viper, elapids, lancehead vipers)</td>
</tr>
<tr>
<td>Consumption of blood clotting factors, thrombocytopenia</td>
<td>Venom-induced consumption coagulopathy Systemic bleeding including epistaxis, gingival, gastrointestinal, intracranial bleeding</td>
<td>Viperids, some colubrids (eg, boomslangs and vine snakes)</td>
</tr>
<tr>
<td>Vasoactive substances in venoms or release of endogenous vasoactive substances</td>
<td>Increased in vascular permeability</td>
<td>Viperids, atractaspids</td>
</tr>
<tr>
<td>Renal effects</td>
<td>Renal impairment from direct nephrotoxicity, shock, thrombotic microangiopathy, hypovolaemia, rhabdomyolysis</td>
<td>Viperids (Russell’s viper, South American rattlesnake) Elapids (New Guinea small-eyed snakes, Australian tigers snakes, black snakes and taipans)</td>
</tr>
</tbody>
</table>
The diagnosis of snakebite envenoming can be challenging in paediatric cases. In many countries, a syndromic approach is successfully used. This means the child’s clinical and laboratory abnormalities suggest the type of snake responsible for the bite, which in turn helps to select the appropriate antivenom. Only a small number of high-income countries, such as Australia, have enzyme immunoassay tests to identify the presence of a specific snake venom. These tests are particularly useful when the local snake fauna is diverse, the clinical manifestations from various snake bites are similar, and specific antivenom is needed.

Envenomated children may not present with a clear history of snakebite, but present with paralysis, seizures or coagulopathy of unknown aetiology. A high index of suspicion should be maintained, especially in children with coagulopathies of unknown origin that persist despite treatment. Examining the entire body surface of the child thoroughly—including scalp—for the presence of fang marks is essential. However, fang marks or local pain may not be evident in some snake envenoming, such as krait (Bungarus). In rural South and Southeast Asia, children with krait envenoming often present with abdominal pain and early neurological signs.

Management at a health facility
When a child arrives in hospital, an ABCDE (airway, breathing, circulation, disability, exposure) approach should be followed initially. Key points from the history should include the time of the bite, a description or photograph of the snake (see figure 3), first-aid measures that were used, other medical conditions and food or drug allergies.

The provision of adequate analgesia is essential although some snakes cause almost no local pain or tissue necrosis during envenoming. Most opioids and benzodiazepines should be avoided in any neurotoxic envenomings and most haemotoxic bites (ie, those associated with bleeding and coagulopathies) due to reported venom potentiation but may have a role in cytotoxic bites. Ketamine is a safe analgesic commonly used in low and middle income country settings. A quick bedside test for suspected bites from haemotoxic snakes is the 20 min whole blood clotting test. If the blood clots, then the risk of haemotoxic envenoming is unlikely.

The child should receive supportive care and be closely and frequently monitored (see table 2), particularly for evidence of airway or respiratory compromise, progressive paralysis, hypotension or cardiovascular collapse, bruising or bleeding and kidney impairment.

If significant neurotoxic envenoming has occurred, then early intubation and ventilation is advocated. Antivenom administration may reduce the time of ventilation from an average of 7 to 4 days. Early use of renal replacement therapy for oliguric or hyperkalemic acute kidney injury is advised where available.

The use of antibiotics continues to be controversial, but broad-spectrum antibiotics may be recommended, particularly in tropical countries, where the incidence of bacterial infections of snakebite wounds is higher. Their role can also be argued in cases of cytotoxic syndromes once the necrosis is established to prevent subsequent wound infection.

Intramuscular injections should not be given when a coagulopathy is present. Tetanus toxoid and tetanus immunoglobulin should be given early if the child is not immunised.

Once antivenom therapy is administered, the response to the medication must be carefully assessed. If possible, consultation with a regional toxinoologist or paediatrician with experience in dealing with snakebites is recommended.

Antivenom
Antivenom is the only specific treatment to reverse or prevent the dangerous effects of snakebite and is highly efficacious in most cases if administered in a timely fashion. This is highlighted by the inclusion of snake antivenom immunoglobulins in the WHO List of Essential Medicines, meaning it should be available in all settings where venomous snakes are present. Despite this, the availability and accessibility of antivenoms of many regions of sub-Saharan Africa and Asia is very limited. Identification of the snake species to choose the correct antivenom is difficult, as in most cases the snake is not brought to the health facility and in some cases a syndromic approach is used. The majority of antivenoms are, however, polyspecific, that is, able to neutralise venoms of several species from one or more groups of snakes. In Africa and (with few exceptions) most Asian countries, antivenoms are polyspecific for both viper and elapid venoms, whereas in North and Latin America polyspecific antivenoms tend to be for different genera of vipers, while coral snake antivenoms are separate products. In Australia and New Guinea, different species of elapid snakes can cause different envenoming syndromes but a polyspecific antivenom suitable for almost all these species is available, along with a range of monospecific products. Clinicians can often identify the genus of the snake that inflicted the bite based on the clinical and laboratory abnormalities, and the decision on whether or not to administer...
antivenom and which antivenom should be used can be based on this clinical identification. In general, antivenom should, if available, be administered to all patients who have evidence of:

1. Systemic manifestations of envenoming.
2. Severe local and regional effects of envenoming, particularly those with substantial swelling, oedema or skin lesions extending to two major joints from the bite site (e.g. past the knee following a bite on the foot or to the pelvis after a bite above the ankle).

Health workers should be guided by available national or regional snakebite protocols, and if in doubt should seek expert advice.

Antivenom should ideally be administered intravenously by infusion; however where this is not possible, it can be delivered by slow intravenous push at a rate of no more than 2 mL/minute. For intravenous infusion, paediatric burettes or 100 mL normal saline infusion bags are useful for dose dilution and volume-controlled administration in the absence of mechanical infusion pumps. Dosages and regimens of antivenom administration vary and there is a paucity of randomised controlled trials and evidence regarding best use, with none specifically focused on children. Antivenom has reportedly been used in children as young as a 27-day-old neonate. The doses of antivenom used in children are the same as adult doses, as the volume of venom injected does not depend on the size of the victim. However, the volume of saline solution in which antivenom is diluted is generally lower than that used in adult patients to avoid fluid overload. When clinical manifestations of envenoming do not subside several hours after antivenom infusion, the administration of a second dose of antivenom must be considered.

### Reactions to antivenom

Antivenom is associated with both early (type I IgE and non-IgE mediated) acute adverse reactions, and late ‘serum sickness’ reactions (type III hypersensitivity reactions). Acute allergic reactions after antivenom administration occur in 2% to 50% of treated snakebite victims, depending on the type of antivenom and the dose. There is no evidence to support giving antihistamines or hydrocortisone to prevent early adverse reactions to antivenom, although preadministration of epinephrine in high-risk cases may reduce such reactions. When reactions occur, epinephrine should be used, in addition to antihistamines and steroids, with care taken for the sedative effects of first-generation H1 antihistamines. However, none of the randomised controlled trials performed focused on children. Serum sickness typically occurs between 5 and 24 days postadministration of antivenom and involves fever, urticarial rash, arthralgia, malaise, lymphadenopathy and occasionally even renal failure. These reactions generally respond well to prednisolone.

### Surgical care of snakebite management

Once the patient has been assessed and initial supportive management underway as previously described, local wound assessment follows. Surgical wound management is particularly important in cytotoxic bites and with eye-sprays from some of the spitting cobras.

For eye-splashes, extensive eye irrigation with water or milk with the use of topical lignocaine is crucial.

Wounds should be cleaned after any required swabs or specimens are taken, preferably with a chlorhexidine-based antiseptic. The wound should be inspected for bleeding, skin necrosis, blistering and firmness of surrounding compartments. All wounds will demonstrate some degree of inflammation, and very early infection is unlikely. Current surgical practice is to deroof blisters and wash wounds, covering them with a non-adherent silver-containing (or honey-based) dressing. The wounds should be inspected for progression in the first 24 hours, thereafter reviewing at least every 48 hours. Only once the wound edges demarcate (around day 5–7 postbite) should formal conservative debridement be performed. Various vacuum-assisted closure techniques allow granulation tissue to develop and reduce wound sepsis rates. Split skin grafting or tissue flaps may be required at a later date.

Fasciotomy is often advocated for cytotoxic bites but is actually seldom required. Clinical assessment of peripheral perfusion includes capillary refill time and palpation for peripheral pulses and compartment tightness. However, the diagnosis of compartment syndrome in small children is particularly difficult. Fasciotomy should not be performed without first assessing the compartment pressures; this can be done using either a commercially purchased device or homemade versions, for example, a cannula introduced into the compartment and connected to a pressure transducer or manometer. If fasciotomy is indicated, it must be completed in each compartment in the relevant limb and should be performed in conditions where replacement of coagulation factors is available if indicated in a patient with coagulopathy.

### Traditional medicine

Traditional methods to deal with snakebite envenoming include local incisions, herbal remedies, use of tourniquets (see figure 4), oral suction at the bite, recitation of mantras and electric shock. These are ineffective, but some of these can be harmful causing tissue necrosis, bleeding or infection. The use of traditional healers often leads to delays in accessing effective conventional medical treatment (including antivenom), commonly with delays of more than 1 day between snakebite and medical facility attendance in sub-Saharan Africa. Delayed presentation at health facilities due to diversion to traditional practitioners can lead to fatal outcomes.

---

**Table 2 Monitoring and supportive care considerations**

<table>
<thead>
<tr>
<th>Cardiovascular</th>
<th>Pulse, blood pressure, capillary refill time, urine output, ECG</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respiratory</td>
<td>Airway patency and protection, oxygen saturation, ventilation adequacy, pulmonary function tests (peak flow and inspirometers), blood gases, capnography if ventilated</td>
</tr>
<tr>
<td>Neurological</td>
<td>Cranial nerves examination, peripheral neurological examination, pain (avoid opiates where possible)</td>
</tr>
<tr>
<td>Laboratory investigations</td>
<td>Blood (full blood count), prothrombin time/INR, APTT, fibrinogen, D-dimer, urea, creatinine, creatine kinase, electrolytes, calcium, phosphates, uric acid, haemoglobinuria, myoglobinuria (in low-income settings, these may differ, with tests such as 20 min whole blood clotting test (WBCT 20 min) and packed cell volume more readily available)</td>
</tr>
<tr>
<td>Local site</td>
<td>Assessment for infection, swelling, tissue necrosis, early surgical involvement if debridement necessary, compartment pressures if clinical suspicion of compartment syndrome</td>
</tr>
</tbody>
</table>
CONCLUSION

Most deaths and serious sequelae related to snakebites are preventable if there is treatment (safe and effective antivenom and supportive care) available locally, and if there are health staff trained in the management of snakebite envenoming.

The management of snakebite envenoming faces significant challenges as it disproportionatly affects those in rural communities in low-income countries. Community education of prehospital first aid and the potential negative impact of traditional medicine are crucial. Globally most healthcare settings manage cases of snakebite envenoming using a syndromic approach. Paediatric cases are particularly challenging to manage clinically due to the lower volume of distribution of venom and the potential for lifelong permanent sequelae from tissue damage. Much work needs to be done to look specifically at antivenom dosing and regimens, as well as ancillary therapies, in children.

Author affiliations
1 Paediatric Emergency Medicine, Chelsea and Westminster Healthcare NHS Trust, London, UK
2 General Medicine, Royal Free London NHS Foundation Trust, London, UK
3 Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José, Costa Rica
4 African Center of Excellence on Population Health and Policy, Bayero University, Kano, Nigeria

Case vignette

A boy aged 5 years, Aung, was walking in sandals playing in the long grass on the way to school in rural Myanmar, when he was bitten by a snake on his lower leg. His teenage brother, Kyaw, saw the snake retreating, and took a photograph (see figure 5) on his mobile phone.

What first aid could the brother attempt?
Kyaw carried Aung back to their local village over the following half hour, where a traditional healer was summoned, who performed several local incisions. However, Aung’s leg pain continued to get worse over the next few hours, and he became drowsy. His vomiting began to contain blood, his eyes became bloodshot, and he began bleeding from his gums.

What type of signs was Aung beginning to show? What other signs might you expect?
The decision was made to travel to the nearest medical facility, which was 2 hours away, in the village shop's pick-up truck. He continued to vomit throughout the journey, with increasing amounts of blood. By the time Aung arrived at the medical facility, he had bilateral ptosis, and generalised muscle pain and tenderness.

As the receiving clinician at this small health facility, how would you assess and treat this child?
Aung received a careful assessment and regular monitoring of his airway, respiratory effort, pulse, blood pressure, capillary refill time, urine output, and central and peripheral neurological examinations. He was given oxygen but did not require any additional ventilatory support. Intravenous fluids were required for the first 24 hours to treat hypovolaemia. Basic blood tests for FBC, renal function, and coagulation were able to be performed every 48 hours.

Despite the facility having been out of stock of antivenom for months, luckily a delivery had been made that week. Aung received antivenom, bought with donations made by relatives and neighbours. He was successfully discharged from hospital a week later.

1. Department of Biochemistry, University of Peradeniya, Peradeniya, Kandy, Sri Lanka
2. Trauma Service, Inkosi Albert Luthuli Central Hospital, Durban, South Africa
3. Department of Surgery, University of KwaZulu-Natal, Durban, South Africa
4. Pediatrics, Hospital Nacional Cayetano Heredia, Lima, Peru
5. Pediatric Infectious Diseases, Hospital Nacional de Niños, San Jose, Costa Rica
6. Children’s Hospital, New Haven, Connecticut, USA
7. Department of Paediatric Nephrology, University of Medicine, Mandalay, Myanmar
8. Department of Paediatrics, Royal London Hospital, London, UK

Twitter Timothy Craig Hardcastle @vemadoc, Maria Luisa Avila-Aguero @maluavi and Kyaw Thu Ya @Kthura_ped@gmail.com

Contributors The idea for this paper was formulated by the lead author JH. All coauthors were involved in the design of the paper. An initial literature review was performed by JH and then further updated by all coauthors. The first draft of the paper was written by SP, JLG, and JH. This was then reviewed and revised by all coauthors.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement  No data are available. Review article.

ORCID iDs
Jacqueline Le Geyt http://orcid.org/0000-0001-9540-9463
Maria Luisa Avila-Aguero http://orcid.org/0000-0002-1979-0431
Jay Halbert http://orcid.org/0000-0003-1048-5876

REFERENCES